• Concerning the molecular mechanisms underlying transcription

  2022-05-21

  

  Concerning the molecular mechanisms underlying transcriptional regulation of the GSTP1-1 gene expression we and others have characterized structural and functional properties of the human GSTP1-1 promoter. GSTP1-1 gene promoter activity is driven by a TATA-box [16] as well as Spl [16], [17], AP-1 [1

• br Medium and long chain fatty acid receptors br Clinical

  2022-05-21

  

  Medium- and long-chain fatty Glycopyrrolate receptors Clinical studies of ω3 fatty acids Clinical studies have established that dietary intake of ω3 fatty acids should be around 4g/day for treating very high triglyceride levels (≥5.7mmol/L) [36]. Low-dose supplementation with EPA + DHA (400mg/

• br Gastrointestinal peptides and intestinal health Gastroint

  2022-05-21

  

  Gastrointestinal peptides and intestinal health Gastrointestinal peptides are intimately involved in the regulation of feeding behaviors, energy metabolism and bodyweight 36, 37, 38, 39, 40, 41. GPR120 has been demonstrated to induce secretion of two such peptides: GLP-1 and cholecystokinin (CCK)

• A general synthetic pathway to

  2022-05-21

  

  A general synthetic pathway to these tricyclic structures is described in (detailed procedures can be accessed in the patent application WO 2011/014520 A2). Benzylation of the appropriate ketoester using KHMDS, followed by treatment with DMF-dimethyl acetal yielded the racemic (dimethylamino)-methy

• Curcumin is the active ingredient extracted

  2022-05-21

  

  Curcumin is the active ingredient extracted from the natural medicine turmeric rhizome (Goel et al., 2008, Aggarwal and Harikumar, 2009). Studies have shown that curcumin has anti-tumor, anti-inflammatory, antioxidant and antimicrobial properties (Larsen et al., 2007, López-Lázaro, 2008). Although c

• br Introduction The amino acid

  2022-05-21

  

  Introduction The amino pergolide glycine functions as a neurotransmitter in the vertebrate central nervous system: as an inhibitory neurotransmitter and as a co-agonist of the NMDA-subtype of excitatory glutamatergic receptors (Eulenburg et al., 2005). Under a current hypothesis that schizophreni

• The discovery that GLUT in the

  2022-05-21

  

  The discovery that GLUT1 in the microvasculature represents an important target of VEGF thereby affecting Vicriviroc Malate function is highly relevant. The work of Jais et al. identified VEGF as a determining player in the regulation of cognitive performance and provides an important link to the u

• As early as glucagon was shown

  2022-05-21

  

  As early as 1957, glucagon was shown to increase 9-Phenanthrol mg expenditure in rodents in both pair-feeding studies and through directly increasing oxygen consumption [23], [24]. This has more recently been confirmed in man, through indirect calorimetry during glucagon infusions [25], [26], [27].

• Given the actions of GIP

  2022-05-21

  

  Given the actions of GIP analogues administered as a single dose to ob/ob mice, studies were performed to assess their ability to act in vivo as antagonists of GIP-induced insulinotropic and antihyperglycaemic actions. (Ala3)GIP, (Phe3)GIP, (Tyr3)GIP and (Pro3)GIP all counteracted the glucose-loweri

• GLP is released in response to ingestion of nutrients includ

  2022-05-21

  

  GLP-1 is released in response to ingestion of nutrients including carbohydrates, protein, and fat. Recent studies aimed at identifying the receptors involved in nutrient stimulated GLP-1 secretion have identified free fatty pathways cu sale receptor 4 (FFA4/GPR120) as a potential 7TM receptor invol

• Compound and several additional FPR antagonists identified

  2022-05-21

  

  Compound 10 and several additional FPR1 antagonists identified here specifically blocked fMLF-induced responses mediated via FPR1 in FPR1-HL60 Cy3 azide and human neutrophils, but not responses mediated via FPR2 or FPR3 (in human neutrophils and transfected HL60 cells) or Fpr1 (murine neutrophils a

• br Resistance to targeted therapy The idea of treating HER

  2022-05-20

  

  Resistance to targeted therapy The idea of treating HER2 mutant tumors with specific therapies is relatively new and, as a consequence, little is known about the potential mechanisms of resistance to anti-HER2 agents in this setting. Primary resistance may be mediated by the presence of on-target

• antifungal Immunohistochemical evaluation of gastric cancer

  2022-05-20

  

  Immunohistochemical evaluation of gastric cancer tumor samples revealed that 57.8% (59/101) were positive for GLI1, and 71.3% (72/101) stained positive for SHH [27]. Overexpression of SHH and GLI1 protein were significantly associated with larger tumor size, tumor aggressiveness, and less differenti

• The LOD and linear range of the cobas HBV

  2022-05-20

  

  The LOD and linear range of the cobas HBV test using the cobas 4800 system in this study were similar to those provided by the manufacturer. We found a strong correlation between the results of the cobas HBV test and CAP/CTM v2.0 systems; however, 7.7% of samples yielded detectable results only with

• In the inhibitory kinetic studies five different concentrati

  2022-05-20

  

  In the inhibitory kinetic studies, five different concentrations of DEL carefully selected from the near-linear region of the dose–response curve (0.5 μM, 1.0 μM, 2.0 μM, 4.0 μM, and 8.0 μM) were used. The Vm values at fixed [CDNB]–varied [GSH] and at fixed [GSH]–varied [CDNB] were 10.4 ± 0.22 U mg−

8357 records 476/558 page Previous Next First page 上5页 476477478479480 下5页 Last page